Kathryn Wengel Sells 10,000 Shares of Johnson & Johnson (NYSE:JNJ) Stock

Posted by Brenda Bartman on Jun 12th, 2026

Johnson & Johnson (NYSE:JNJ – Get Free Report) EVP Kathryn Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Johnson & Johnson Trading Up 0.9%

JNJ traded up $2.24 during midday trading on Friday, hitting $240.57. 6,458,432 shares of the company were exchanged, compared to its average volume of 8,314,816. The firm has a market capitalization of $579.10 billion, a P/E ratio of 27.81, a P/E/G ratio of 2.34 and a beta of 0.26. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The firm’s 50 day moving average price is $231.58 and its 200-day moving average price is $227.11. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, May 26th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Greenberg Financial Group purchased a new position in Johnson & Johnson in the fourth quarter worth $954,000. Varma Mutual Pension Insurance Co increased its position in shares of Johnson & Johnson by 8.9% during the 3rd quarter. Varma Mutual Pension Insurance Co now owns 378,256 shares of the company’s stock valued at $70,136,000 after purchasing an additional 30,900 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Johnson & Johnson by 4.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,030,835 shares of the company’s stock worth $932,835,000 after purchasing an additional 208,765 shares during the period. JT Stratford LLC grew its position in Johnson & Johnson by 7.6% during the third quarter. JT Stratford LLC now owns 59,577 shares of the company’s stock valued at $11,047,000 after buying an additional 4,216 shares during the period. Finally, World Investment Advisors grew its position in Johnson & Johnson by 19.6% during the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after buying an additional 26,450 shares during the period. 69.55% of the stock is owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson agreed to pay about $1 billion for Firefly Bio technology, a bet on improving treatment options for one of cancer’s most hard-to-target areas. Article Title
Positive Sentiment: J&J also reported encouraging late-stage results for IMAAVY in warm autoimmune hemolytic anemia, reinforcing the company’s pipeline momentum in rare diseases. Article Title
Positive Sentiment: Analysts and commentators highlighted J&J as a defensive healthcare name with attractive valuation and dividend appeal, which can support buying interest in a volatile market. Article Title
Neutral Sentiment: Jim Cramer mentioned J&J while favoring healthcare over technology, which is a sentiment tailwind but not a direct company-specific catalyst. Article Title
Neutral Sentiment: Johnson & Johnson expanded U.S. availability of its TECNIS PureSee cataract lens, a positive commercial update but likely a smaller stock mover than the acquisition and pipeline news. Article Title
Negative Sentiment: Ongoing talc-related legal headlines remain an overhang and could limit upside if investors focus back on litigation risk. Article Title

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research report on Wednesday, May 13th. HSBC lifted their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Finally, Rothschild & Co Redburn lifted their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research report on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Get Our Latest Stock Analysis on JNJ

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.